Dyne Therapeutics, Inc. (DYN): debt financing — Dyne Therapeutics enters $275M loan agreement with Hercules Capital; $100M funded immediately

Dyne Therapeutics, Inc.

Initial tranche of $100M funded on June 27, 2025; additional tranches up to $175M available upon milestones and lender discretion.
Interest rate of WSJ Prime + 2.45% (floor 7.50%); maturity July 1, 2030; interest-only until July 1, 2028, extendable.
First-priority security interest on substantially all assets including IP; covenants include minimum cash and minimum net product revenue post-approval of DYNE-101 or DYNE-251.
Prepayment penalty ranges from 0.75% to 2.0% of prepaid amount; end-of-term charge of 5.5%.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Dyne Therapeutics, Inc. incurred credit facility of up to $275.0 million with Hercules Capital, Inc. at Wall Street Journal prime rate, subject to a floor of 7.50%, plus 2.45% maturing July 1, 2030.

Instrument: credit facility
Principal: up to $275.0 million
Counterparty: Hercules Capital, Inc.
Rate: Wall Street Journal prime rate, subject to a floor of 7.50%, plus 2.45%
Maturity: July 1, 2030
Event: incurrence

Exact text from the filing

The Loan Agreement provides for term loans in an aggregate principal amount of up to $275.0 million under multiple tranches

View on SEC.gov

10 debt financings filed in the last 30 days. Browse all debt financings →

Dyne Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-152652

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.